SecBot SecBot
8-K ·Filed Jul 27, 2026

NMRA

Neumora Therapeutics, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed3mo ago SEC0001193125-26-316819
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The favorable toxicology results de-risk the NMRA-215 program and support the IND timeline. Traders should monitor for the IND submission in Q4 2026 and subsequent Phase 1 initiation, which could drive further upside if clinical data is positive. Given the company's small market cap (~$276M), positive pipeline news may have outsized impact.

DirectionBullish
Confidencemedium
Horizonmonths

NMRA-215

● Neutral Named in this 8-K
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.66
T+0 close · Jul 27, 2026 · via day close
Latest settled
−71.69%
T+60 · $0.4700
Vs SPY
−75.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $1.66entry
  2. T+1 · 4mo ago +1.20%α +0.97% · $1.68
  3. T+5 · 4mo ago −3.01%α −4.09% · $1.61
  4. T+20 · 3mo ago −8.13%α −11.43% · $1.53
  5. T+60 · 28d ago −71.69%α −75.39% · $0.4700
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor in development for obesity and cardiometabolic disease. A repeat 13-week rat study found no unexpected adverse findings, clearing a key safety concern and enabling the company to plan an IND submission in Q4 2026 with a Phase 1 study by end of 2026. This removes a significant pipeline risk and supports advancement toward the clinic.

Key Facts

  • Repeat 13-week rat toxicology study (162 animals) showed no unexpected in-life adverse findings, resolving concerns from a prior study where 5 of 142 animals had adverse events.
  • Company opened a for-cause audit of the prior study, which revealed discrepancies; management believes prior findings were not related to NMRA-215.
  • Plans to submit an IND for NMRA-215 in Q4 2026 and initiate a Phase 1 study by the end of 2026.
  • NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disease with pre-clinical data showing class-leading weight loss and additive effects with semaglutide.

Financial Impact

No financial data provided; the event is a pre-clinical pipeline milestone with no revenue impact. Positive catalyst for stock valuation but no direct financial figures.

Risk Factors

  • Pre-clinical data may not translate to clinical success; NMRA-215 still faces Phase 1 safety and efficacy hurdles.
  • Competition from other NLRP3 inhibitors and obesity treatments (e.g., incretins) could limit commercial potential.
  • Company is pre-revenue with no financial data provided; cash runway and need for future financing are not addressed in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-316819
Document: nmra-ex99_1.htm0001193125-26-316819
Document: 0001193125-26-316819-index-headers.html0001193125-26-316819
Document: 0001193125-26-316819-index.html0001193125-26-316819
Document: 0001193125-26-316819.txt0001193125-26-316819

Track record

14 reports on NMRA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Viewing Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026